creb

Crebinostat is a potent histone deacetylase (HDAC) inhibitor, targeting HDAC1, HDAC2, HDAC3, and HDAC6 with IC50s of 0.7 nM, 1.0 nM, 2.0 nM, and 9.3 nM, respectively. It increases the density of synapsin-1 punctae along dendrites in neurons in vitro, modulates chromatin-mediated neuroplasticity, and enhances memory in mice. Additionally, Crebinostat induces histone H3 and H4 acetylation and enhances the expression of Egr1, a cAMP-responsive element binding protein (CREB) target gene.

PF-CBP1 HCl is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP). It inhibits CREBBP (IC50: 125 nM) and p300 bromodomains (IC50: 363 nM).

XX-650-23 is a small molecule CREB inhibitor that blocks the critical interaction between CREB and its required coactivator, CBP (CREB-binding protein), inducing apoptosis and cell cycle arrest in AML cells, and can be used in the study of acute myelogenous leukaemia (AML).

666-15 is a selective CREB inhibitor with an IC50 of 81 nM. 666-15 can effectively inhibit the growth of breast cancer.

KG-501 (Naphthol AS-E phosphate) is a cAMP response element-binding protein (CREB) inhibitor(IC50 : 6.89 μM).

CREB-IN-1 TFA is a potent and orally active CREB inhibitor with an IC50 of 0.18 μM, exhibiting inhibitory effects on the growth of breast cancer cells.

PI3K Akt CREB activator 1 (AE-18) is a selective inducible nitric oxide synthase (iNOS) inhibitor that crosses the blood-brain barrier, reduces infarct size and restores blood supply deficits after ischemia-reperfusion in rats, and is used in studies of vascular dementia and Parkinson's disease.

CREBtide acetate is a synthetic substrate for PKA (Km=3.9 μM), which is based on the phosphorylation sequence in d-CREB (cAMP response element binding protein).

CREBtide is a synthetic substrate for PKA (Km=3.9 µM), which is based on the phosphorylation sequence in d-CREB (cAMP response element binding protein).

Crebanine N-oxide is a useful organic compound for research related to life sciences. The catalog number is T126510 and the CAS number is 102719-85-7.

CREBBP-IN-9, a CREBBP inhibitor, acts on the bromodomain of the protein.

Tylocrebrine is anticancer agent.

1. Crebanine iv 5mg/kg can eonvert BaCl_2-induced arrhythmia into sinus rhythm in rats, and can significantly increase the tolerant dose of aconitine to produce ventrieular fibrillation(VF) and cardiac arrest (CA) in rata. 2. Crebanine can also decrease t

Ep300 CREBBP-IN-8 (Example 37), a potent and orally active inhibitor of Ep300 and CREBBP, shows IC50 values of 0.014 μM and 0.018 μM, respectively, and is utilized in cancer research [1].

Ep300 CREBBP-IN-2 (Example 73) is a potent, orally bioavailable inhibitor of Ep300 and CREBBP, with IC50 values of 0.052 μM and 0.148 μM, respectively, and is used in cancer research [1].

Ep300 CREBBP-IN-3 (Example 61), a potent inhibitor of Ep300 and CREBBP with IC50 values of 0.056 μM and 0.095 μM, respectively, is applicable in cancer research [1].

Ep300 CREBBP-IN-4 (Example 56), a potent inhibitor of both Ep300 and CREBBP, shows IC50 values of 0.024 μM and 0.064 μM, respectively, and is employed in cancer research [1].

Oxocrebanine, an aporphine alkaloid present in Fissistigma poilanei (Annonaceae) [1], is identified as a constituent of this botanical species.

Crebankitug is a humanized IgG1λ2 type antibody targeting IL7R, with HumanIgG1lambda2, Isotype Control serving as the corresponding isotype control.

Dehydrocrebanine has strong activity against promyelocytic leukemia cells (HL-60) with an IC50 of 2.14 ug mL. It also shows potent antimalarial activity with an IC50 value of 70 ng ml.

Brefeldin A (Cyanein) belongs to the class of macrolide antibiotics and is an ATPase inhibitor (IC50=0.2 μM). Brefeldin A can induce tumor cell differentiation and apoptosis, and also possesses autophagy inhibitory activity.

L-692429 (MK-0751) is a potent nonpeptidyl growth hormone secretagogue (GHS) agonist and benzolactam derivative, known for reversing glucocorticoid-induced inhibition of GH secretion. L-692429 exhibits high affinity for the G protein-coupled receptor and is useful in studying acromegaly and obesity.

GNE-049 is a highly selective and potent inhibitor designed to target the CREB-binding protein (CBP) with high affinity, exhibiting an IC50 of 1.1 nM for the suppression of BRET and BRD4 activity, which consequently blocks prostate cancer cell proliferation in both in vitro and in vivo models.

RMM-46 is a reversible covalent inhibitor with high ligand efficiency and selectivity for MSK/RSK family kinases.